文献速递慢性肾脏病肾小球疾病

GLP-1受体激动剂与多激素受体调节剂在非糖尿病肾病中的肾脏保护作用

Glucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2026-10-19

本综述探讨GLP-1受体激动剂及多激素受体调节剂在非糖尿病人群中的肾脏保护机制与临床证据。肾脏保护通过直接(利钠、调节肾小球血流动力学、抗炎)和间接(减重、降压、改善心衰)途径实现。现有疗效证据来自3期肥胖和心血管结局试验的次要肾脏终点(如降低白蛋白尿、保持eGFR),多项专门结局研究正在进行。

要点

  • GLP-1受体激动剂和多激素受体调节剂在非糖尿病人群中显示降低白蛋白尿和保持eGFR的次要终点获益。
  • 肾脏保护机制包括抑制NHE-3利钠、调节肾小球血流动力学和抗炎,部分不依赖降糖。
  • 多激素成分的相互作用可能相加、协同或拮抗,但尚未完全阐明。

核心结论

  • GLP-1受体激动剂和多激素受体调节剂在非糖尿病肾病中具有肾脏保护潜力,但需专门结局研究确认。

研究设计与样本

  • 本综述总结了GLP-1受体激动剂和多激素受体调节剂在非糖尿病人群中的肾脏保护机制和新兴临床证据。

主要发现

  • 肾脏保护通过直接机制(抑制NHE-3利钠、调节肾小球血流动力学、抗炎)和间接机制(减重、降压、改善心衰)实现。
  • 非糖尿病人群的疗效证据来自3期肥胖和心血管结局试验的次要肾脏终点,包括降低白蛋白尿和保持eGFR。
  • 多激素受体调节剂中附加激素成分的相互作用可能相加、协同或拮抗,但尚未完全阐明。

临床怎么用

  • 在非糖尿病肾病患者中,GLP-1受体激动剂和多激素受体调节剂可作为潜在治疗选择,但需等待专门结局研究结果。

局限性

  • 非糖尿病人群的疗效证据仅来自次要肾脏终点,缺乏专门结局研究。
  • 多激素受体调节剂中激素成分的相互作用机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), together with newer multi-hormone receptor modulators that target glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin, have emerged as promising therapies for chronic kidney disease. This review examines the mechanisms through which these agents may protect the kidney and summarizes the emerging clinical evidence in populations without diabetes. Kidney protection appears to arise through complementary direct and indirect routes. Direct effects include natriuresis through inhibition of the sodium-hydrogen exchanger (NHE)-3, modulation of glomerular hemodynamics through effects on afferent arteriolar tone and vasoconstrictor pathways, and attenuation of renal inflammation; mechanisms that are largely independent of glucose lowering. Indirect mechanisms include reductions in the metabolic, hemodynamic and cardiac burden on the kidney through weight loss, blood pressure lowering, and improvement of heart failure. Beyond selective GLP-1R-agonism, the added hormonal components of multi-hormone receptor modulators engage distinct physiological pathways whose interactions may be additive, synergistic or counteracting, but remain incompletely understood. The efficacy of GLP-1 RAs and multi-hormone receptor modulators in people without diabetes is currently supported by results from secondary kidney endpoints in phase-3 obesity and cardiovascular outcome trials, including reductions in albuminuria and preservation of estimated glomerular filtration rate. Several dedicated outcome studies of GLP-1 RAs and multi-hormone receptor modulators are now underway and will determine whether these therapies become a new pillar of care in nondiabetic kidney disease.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Pasricha SV, Faruque LI, Mohsen M, et al. Glucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease. J Am Soc Nephrol. 2026. PMID: 42895792. doi:10.1681/ASN.0000001306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。